Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain

Tools
- Tools
+ Tools

Richards, Mark, O'Regan, Laura, Roth, Daniel, Montgomery, Jessica, Straube, Anne, Fry, Andrew and Bayliss, Richard (2015) Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. Biochemical Journal, Volume 467 (Number 3). pp. 529-536. doi:10.1042/BJ20150039

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1042/BJ20150039

Request Changes to record.

Abstract

Proteins of the echinoderm microtubule (MT)-associated protein (EMAP)-like (EML) family contribute to formation of the mitotic spindle and interphase MT network. EML1-4 consist of Trp-Asp 40 (WD40) repeats and an N-terminal region containing a putative coiled-coil. Recurrent gene rearrangements in non-small cell lung cancer (NSCLC) fuse EML4 to anaplastic lymphoma kinase (ALK) causing expression of several oncogenic fusion variants. The fusions have constitutive ALK activity due to self-association through the EML4 coiled-coil. We have determined crystal structures of the coiled-coils from EML2 and EML4, which describe the structural basis of both EML self-association and oncogenic EML4-ALK activation. The structures reveal a trimeric oligomerization state directed by a conserved pattern of hydrophobic residues and salt bridges. We show that the trimerization domain (TD) of EML1 is necessary and sufficient for self-association. The TD is also essential for MT binding; however, this property requires an adjacent basic region. These observations prompted us to investigate MT association of EML4-ALK and EML1-ABL1 (Abelson 1) fusions in which variable portions of the EML component are present. Uniquely, EML4-ALK variant 3, which includes the TD and basic region of EML4 but none of the WD40 repeats, was localized to MTs, both when expressed recombinantly and when expressed in a patient-derived NSCLC cell line (H2228). This raises the question of whether the mislocalization of ALK activity to MTs might influence downstream signalling and malignant properties of cells. Furthermore, the structure of EML4 TD may enable the development of protein-protein interaction inhibitors targeting the trimerization interface, providing a possible avenue towards therapeutic intervention in EML4-ALK NSCLC.

Item Type: Journal Article
Subjects: Q Science > QD Chemistry
Q Science > QH Natural history
Q Science > QP Physiology
Divisions: Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Cell & Developmental Biology
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Texture (Crystallography) , Microtubules, Tubulins
Journal or Publication Title: Biochemical Journal
Publisher: Portland Press Ltd.
ISSN: 0264-6021
Official Date: 1 May 2015
Dates:
DateEvent
1 May 2015Published
Volume: Volume 467
Number: Number 3
Number of Pages: 8
Page Range: pp. 529-536
DOI: 10.1042/BJ20150039
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Royal Society (Great Britain), Cancer Research UK (CRUK), Marie Curie Cancer Care, Lister Institute of Preventive Medicine, Worldwide Cancer Research (Organization), Wellcome Trust (London, England)
Grant number: UF090021 (Royal Society (Great Britain)) ; C24461/A12772 (CRUK) ; 13-0042 (Worldwide Cancer Research (Organization)) ; 082828 (Wellcome Trust (London, England))

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us